急性淋巴细胞白血病49例染色体核型和免疫分型的分析

Karyotype and immunophenotype analysis in 49 cases of acute lymphocytic leukemia

目的探讨急性淋巴细胞白血病(ALL)患者染色体异常及免疫分型与疗效的关系。方法对49例ALL患者骨髓进行染色体及免疫分型分析。结果儿童ALL伴有t(9;22)异常核型的检出率明显低于成人ALL(P<0.05),但疗效差异无统计学意义(P>0.05);伴有t(9;22)的异常核型与正常核型ALL疗效比较差异有统计学显著意义(P<0.05);伴或不伴有髓系抗原表达的ALL疗效比较差异无统计学意义(P>0.05)。结论 ALL患者染色体核型异常的检出率较高,较常见的核型异常为t(9;22);核型异常与疗效有一定的关系,伴有t(9;22)核型异常的ALL疗效差,而其它异常核型的ALL疗效间差异无统计学意义(P>0.05)。

Objective To investigate the relationship between the efficacy and the karyotype and immunophenotype in acute lymphocytic leukemia（ALL）. Methods A total of 49 bone marrow samples were taken for the karyotype and immunopbenotype analysis. Results The detected rate of abnormal karycotype with t （9;22） in ALL children was significantly lower than that in ALL adult （ P 〈 0. 05 ）, but no difference in efficacy （ P 〉 0. 05 ） ; There was differences in efficacy between the abnormal karyotype with t （9 ; 22 ） and normal karyotype （ P 〈 0. 05 ） ; There was no difference in efficacy between acute lymphocytic leukemia with and without myeloid antigen expression （P 〉 0. 05）. Conclusion There was a higher rate of abnormal chromosome karycotype in patients with ALL, the more common chromosomal abnormal karycotype was t （9;22）. There was a relationship between chromosomal abnormal karycotype and the efficacy. The efficacy was poorer in chromosomal abnormal karycotype accompanied by t（9 ;22） in ALL, while there was no difference in efficacy between other abnormal karyotypes in ALL.